Clinical Trial Update: Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability evaluation of LEO 138559 in healthy subjects and participants with Atopic dermatitis. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• LEO 138559

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED